• Publications
  • Influence
Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
AimThe aim of this study was to obtain pharmacogenetic data in a Vietnamese population on genes coding for proteins involved in the elimination of drugs currently used for the treatment of malariaExpand
  • 47
  • 7
Artemisinin and CYP2A6 activity in healthy subjects
ObjectiveTo investigate whether the antimalarial drug artemisinin affects CYP2A6 activity in healthy subjects and to compare the utility of coumarin and nicotine as in vivo probe compounds forExpand
  • 28
  • 4
The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial
Background p38 mitogen-activated protein kinase (MAPK) plays a central role in the regulation and activation of pro-inflammatory mediators. COPD patients have increased levels of activated p38 MAPK,Expand
  • 15
  • 1
  • PDF
Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848
Background Many patients with asthma have a T-helper type 2 (Th2) driven inflammation of the lung, whereas toll-like receptor 7 (TLR7) agonists, by inducing type I interferons, inhibit Th2 responses.Expand
  • 13
AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure
Inhaled drugs generally aim to drive a local pharmacological effect in lung, at the same time minimizing systemic exposure, in order to obtain efficacy in lung disease without unwanted systemicExpand
  • 2
The development of aZD 7624 for prevention of exacerbations in COPD : a randomized controlled trial
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms.Expand
  • 4
Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers
AZD8154 is an inhaled PI3Kgd inhibitor developed for treatment of asthma. This first in human study evaluate the safety, tolerability and PK of AZD8154 in healthy volunteers after inhalation ofExpand
Prediction of human lung PK for AZD7624, an inhaled P38 inhibitor for the treatment of COPD
Inhibition of p38 mitogen-activated protein kinases has been suggested as novel treatment for COPD. However, since p38 has high expression in tissues other than lung, local delivery may be crucialExpand
A Phase 2a, Double-Blind, Placebo-Controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma.
RATIONALE To examine the potential of TLR9 activation to modulate the Type-2 immune response in asthma. OBJECTIVES To evaluate efficacy and safety of AZD1419, an inhaled TLR9 agonist, in a phaseExpand
Pharmacogenomics of , , , , , and in Vietnam